PETS
PetMed Express, Inc.
NASDAQ · Healthcare · Medical - Pharmaceuticals · US
$1.80
−2.70%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 168.9M | 179.0M | 227.0M | 274.1M | 256.6M |
| Cost of Revenue | 128.8M | 138.2M | 157.8M | 196.4M | 185.8M |
| Gross Profit | 40.0M | 40.8M | 69.1M | 77.7M | 71.0M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 68.7M | 72.2M | 62.4M | 79.8M | 68.9M |
| General & Admin Expense | 49.0M | 50.7M | 38.6M | 55.2M | 49.5M |
| Selling & Marketing Expense | 19.7M | 21.5M | 23.8M | 24.5M | 19.4M |
| Other Expenses | 2.1M | — | 8.2M | 4.9M | (4.2M) |
| Total Operating Expenses | 70.8M | 72.2M | 70.7M | 84.7M | 64.7M |
| Cost and Expenses | 199.6M | 210.4M | 228.5M | 281.1M | 250.0M |
| Operating Income (EBIT) | (30.8M) | (31.4M) | (1.5M) | (7.0M) | 6.6M |
| Non-Operating | |||||
| Interest Income | 1.3M | 511.0K | — | 511.0K | 450.0K |
| Interest Expense | 443.0K | — | — | — | — |
| Net Interest Income | 813.0K | 511.0K | — | 511.0K | 450.0K |
| Other Non-Op Income/Expense | 1.4M | (25.9M) | 943.0K | 689.0K | 894.0K |
| Non-Operating Income (excl Interest) | 243.0K | — | (1.2M) | (689.0K) | (894.0K) |
| EBT (Pre-Tax Income) | (29.3M) | (57.4M) | (587.0K) | (6.3M) | 7.4M |
| Income Tax Expense | (69.0K) | (73.0K) | 5.7M | 1.2M | 2.3M |
| Bottom Line | |||||
| Net Income | (29.3M) | (57.3M) | (6.3M) | (7.5M) | 5.1M |
| Earnings from Cont. Ops | (29.3M) | (57.3M) | (6.3M) | (7.5M) | 5.1M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (29.3M) | (57.3M) | (6.3M) | (7.5M) | 5.1M |
| Per Share | |||||
| Basic EPS | ($1.38) | ($2.74) | ($0.30) | ($0.37) | $0.25 |
| Diluted EPS | ($1.38) | ($2.74) | ($0.30) | ($0.37) | $0.25 |
| Revenue Per Share | $7.79 | $8.56 | $11.02 | $13.44 | $12.65 |
| Shares | |||||
| Basic Shares Outstanding | 21.7M | 20.9M | 20.6M | 20.4M | 20.3M |
| Diluted Shares Outstanding | 21.7M | 20.9M | 20.6M | 20.4M | 20.3M |
| Profitability Metrics | |||||
| EBITDA | (21.8M) | (22.0M) | 6.7M | 783.0K | 11.0M |
| D&A | 9.3M | 9.4M | 7.0M | 7.1M | 3.5M |
| EBIT | (31.0M) | (31.4M) | (330.0K) | (6.3M) | 7.4M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026